Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 10/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | CDC25B | P30305 | 2/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | CDC25A | P30304 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | CETP | P11597 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1170915 | 1.00 | SELP (0.51) | SELPPTPN1CDC25BPTPN2PTPN6 | |
| SCHEMBL1170916 | 1.00 | SELP (0.51) | SELPPTPN1CDC25BPTPN2PTPN6 | |
| SCHEMBL1170785 | 0.92 | SELP (0.56) | SELPFAAHCETPTHRBMEN1 | |
| SCHEMBL1170905 | 0.92 | SELP (0.58) | SELPFAAHCETPTHRBMEN1 | |
| SCHEMBL1170902 | 0.92 | SELP (0.58) | SELPFAAHCETPTHRBMEN1 | |
| SCHEMBL1170900 | 0.92 | SELP (0.58) | SELPFAAHCETPTHRBMEN1 | |
| SCHEMBL1170783 | 0.92 | SELP (0.56) | SELPFAAHCETPTHRBMEN1 | |
| SCHEMBL1170786 | 0.92 | SELP (0.56) | SELPFAAHCETPTHRBMEN1 | |
| SCHEMBL1170806 | 0.91 | SELP (0.53) | SELPFAAHCETPTHRBMEN1 | |
| SCHEMBL1170807 | 0.91 | SELP (0.53) | SELPFAAHCETPTHRBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211859-B2 | α-galactoceramide analogs, their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-07-03 | — | — | US | disclosed |
| US-20110028411-A1 | ALPHA-GALACTOCERAMIDE ANALOGS, THEIR METHODS OF MANUFACTURE, INTERMEDIATE COMPOUNDS USEFUL IN THESE METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE (FR) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028411-A1 | ALPHA-GALACTOCERAMIDE ANALOGS, THEIR METHODS OF MANUFACTURE, INTERMEDIATE COMPOUNDS USEFUL IN THESE METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GALE, GALNT14, GALC | SELP 4550/4885PTPN1 4777/4885CDC25B 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.